Managing Medico-Legal Risks in ADHD Prescribing
Prescribing ADHD medication can be complex. Australian States and Territories have different laws and regulations regarding stimulant prescribing, which can create challenges for patients who move between jurisdictions, and for clinicians who prescribe across state lines..
In this webinar, our expert panel will explore the key medicolegal risks in prescribing ADHD medications, including documentation and compliance with controlled substances guidelines. They’ll also discuss emerging challenges linked to evolving national policy and share practical strategies to help clinicians manage risk while maintaining safe, patient-focused care.
Learning Outcomes
At the end of this session, participants will be able to:
- Identify key medicolegal risks associated with prescribing ADHD medications.
- Discuss how changes in Australian prescribing regulations impact risk management and collaboration across healthcare teams
- Plan strategies to mitigate risk and minimise medicolegal exposure.
Audience
Whether you actively prescribe ADHD medications or simply want to better understand the legal and clinical considerations, this session will provide practical guidance.
Speakers
Dr Owen Bradfield – Chief Medical Officer, MIPS
Dr Dileni Fernando - Medical Advisor, MIPS
CPD Accreditation
This webinar will be accredited with the RACGP, ACRRM and ACEM.
CPD Recognition for MIPS members
- Pre webinar activity 1-hour Reviewing Performance (RP)
- Live webinar: 1-hour Educational Activity (EA)
- Post-webinar activity: 1-hour Reviewing Performance (RP) + 3-hour Measuring Outcomes (MO). The activity will be provided after the webinar.
This webinar meets the Medical Board of Australia’s program-level requirement for activities in professionalism and ethics.